Next Article in Journal
Survey of Deoxynivalenol Contamination in Agricultural Products in the Chinese Market Using An ELISA Kit
Next Article in Special Issue
Toxin Neutralization Using Alternative Binding Proteins
Previous Article in Journal
Toxins in Fermented Foods: Prevalence and Preventions—A Mini Review
Previous Article in Special Issue
Coagulotoxic Cobras: Clinical Implications of Strong Anticoagulant Actions of African Spitting Naja Venoms That Are Not Neutralised by Antivenom but Are by LY315920 (Varespladib)
Review

Global Availability of Antivenoms: The Relevance of Public Manufacturing Laboratories

Instituto Clodomiro Picado, Facultad de Microbiología, Universidad de Costa Rica, San José 11501-2060, Costa Rica
Received: 16 November 2018 / Revised: 14 December 2018 / Accepted: 20 December 2018 / Published: 24 December 2018
(This article belongs to the Special Issue Snakebite – From Science to Society. Selected papers)
Snakebite envenoming is a serious global public health problem, and international initiatives, under the coordination of the World Health Organization and its regional offices, are being developed to reduce the impact of this neglected tropical disease. The global availability of safe and effective antivenoms is one of the key aspects in this global strategy. This review discusses the role of public antivenom manufacturing laboratories for ensuring the supply of antivenoms. The difficulties faced by public laboratories are discussed, together with some tasks that need to be implemented for strengthening them. In addition, the concept of ‘redundancy’ in the supply of antivenoms is emphasized, as a way to cope with the risks associated with the provision of antivenoms by few manufacturers. In general, the public sector should play a leading role, in antivenom availability and other aspects as well, within the global struggle to reduce the mortality and morbidity caused by snakebite envenoming. View Full-Text
Keywords: antivenoms; snakebite envenoming; public laboratories; availability; preclinical efficacy antivenoms; snakebite envenoming; public laboratories; availability; preclinical efficacy
Show Figures

Graphical abstract

MDPI and ACS Style

Gutiérrez, J.M. Global Availability of Antivenoms: The Relevance of Public Manufacturing Laboratories. Toxins 2019, 11, 5. https://0-doi-org.brum.beds.ac.uk/10.3390/toxins11010005

AMA Style

Gutiérrez JM. Global Availability of Antivenoms: The Relevance of Public Manufacturing Laboratories. Toxins. 2019; 11(1):5. https://0-doi-org.brum.beds.ac.uk/10.3390/toxins11010005

Chicago/Turabian Style

Gutiérrez, José M. 2019. "Global Availability of Antivenoms: The Relevance of Public Manufacturing Laboratories" Toxins 11, no. 1: 5. https://0-doi-org.brum.beds.ac.uk/10.3390/toxins11010005

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop